钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂是 FDA 批准的一类用于糖尿病管理的药物。它们通过诱导糖尿来改善血糖控制。尽管具有有效的抗高血糖活性，但 SGLT2 抑制剂正在成为具有多方面治疗潜力的药物，已被证明具有心脏保护、肾脏保护、抗高血压和神经保护活性。人们不断尝试通过结构修饰、开发新配方或与其他药物组合来增强 SGLT2 抑制剂的生物活性谱，以更好地管理糖尿病和相关并发症。本综述包括使用 Espacenet 获得的专利申请摘要专利检索数据库，涉及 2019 年至 2023 年 SGLT2 抑制剂，重点关注提高糖尿病和代谢并发症管理的治疗潜力。SGLT2 抑制剂为糖尿病提供了令人兴奋的治疗选择。 SGLT2 抑制剂最初是作为抗高血糖药物开发的，可发挥多效性代谢反应，并已成为具有心脏保护和肾保护活性的有前景的抗糖尿病药物。鉴于其独特的治疗特性，SGLT2 抑制剂彻底改变了糖尿病及相关并发症的治疗。越来越多的证据表明它们对癌症、男性生殖功能障碍和神经退行性疾病的治疗潜力表明，这一领域的进一步研究可能会为它们在治疗其他慢性病中的合理用途带来新的前景。

The sodium-glucose co-transporter 2 (SGLT2) inhibitors are FDA-approved class of drugs for diabetes management. They improve glycemic control by inducing glucosuria. Notwithstanding with potent anti-hyperglycemic activity, SGLT2 inhibitors are emerging as drugs with multifaceted therapeutic potential, evidenced for cardioprotective, renoprotective, antihypertensive, and neuroprotective activities. Continuous attempts are being accomplished through structural modification, development of new formulation, or combination with other drugs, to enhance the bioactivity spectrum of SGLT2 inhibitors for better management of diabetes and related complications.This review comprises a summary of patent applications, acquired using the Espacenet Patent Search database, concerning SGLT2 inhibitors from 2019 to 2023, with focus on improving therapeutic potentials in management of diabetes and metabolic complications.SGLT2 inhibitors have provided an exciting treatment option for diabetes. Originally developed as anti-hyperglycemic agents, SGLT2 inhibitors exert pleiotropic metabolic responses and have emerged as promising antidiabetic agents with cardio-protective and reno-protective activities. Given their distinct therapeutic profile, SGLT2 inhibitors have revolutionized the management of diabetes and associated complications. Emerging evidences on their therapeutic potential against cancer, male reproductive dysfunctions, and neurodegenerative diseases indicate that further research in this field may unfold novel prospective on their plausible use in the management of other chronic conditions.